We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+14.73%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$80.2M
Cap. Flow
+$76.6M
Cap. Flow %
21.79%
Top 10 Hldgs %
34.86%
Holding
100
New
24
Increased
44
Reduced
21
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14M
2
LLY icon
Eli Lilly
LLY
+$11.2M
3
EW icon
Edwards Lifesciences
EW
+$7.88M
4
HAE icon
Haemonetics
HAE
+$6.52M
5
CVS icon
CVS Health
CVS
+$6.34M

Top Sells

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$7.01M
2
ALT icon
Altimmune
ALT
+$6.55M
3
AVTR icon
Avantor
AVTR
+$5.36M
4
MASS icon
908 Devices
MASS
+$3.07M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
2 Industrials 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESTA icon
76
Establishment Labs
ESTA
$2.25B
$829K 0.24%
+15,173
New +$907K
OPNT
77
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$823K 0.23%
76,530
+898
+1% +$10.2K
HBIO icon
78
Harvard Bioscience
HBIO
$27.8M
$782K 0.22%
30,535
-4,640
-13% -$154K
LXRX icon
79
Lexicon Pharmaceuticals
LXRX
$1.05B
$729K 0.21%
303,614
+53,614
+21% +$148K
VRDN icon
80
Viridian Therapeutics
VRDN
$2.59B
$725K 0.21%
+35,358
New +$636K
TVTX icon
81
Travere Therapeutics
TVTX
$5.86B
$655K 0.19%
26,565
+315
+1% +$8.14K
CDXS icon
82
Codexis
CDXS
$172M
$638K 0.18%
105,319
-98,730
-48% -$794K
CNSY
83
Cerenome, Inc. Common Stock
CNSY
$25.5M
$590K 0.17%
3,533
-555
-14% -$124K
EWTX icon
84
Edgewise Therapeutics
EWTX
$4.73B
$492K 0.14%
+50,000
New +$505K
TKNO icon
85
Alpha Teknova
TKNO
$397M
$406K 0.12%
121,424
+1,427
+1% +$7.98K
STIM icon
86
Neuronetics
STIM
$223M
$273K 0.08%
+85,866
New +$312K
BLRX
87
BioLineRX
BLRX
$11.7M
$267K 0.08%
7,221
+85
+1% +$4.85K
SIEN
88
DELISTED
Sientra, Inc.
SIEN
$239K 0.07%
37,359
-4,559
-11% -$36.1K
UBX
89
DELISTED
Unity Biotechnology
UBX
$160K 0.05%
+40,409
New +$255K
ALLK
90
DELISTED
Allakos
ALLK
– –
-160,376
Closed -$502K
ALT icon
91
Altimmune
ALT
$570M
– –
-559,755
Closed -$6.55M
AVTR icon
92
Avantor
AVTR
$9.42B
– –
-172,269
Closed -$5.36M
HCAT icon
93
Health Catalyst
HCAT
$135M
– –
-63,104
Closed -$914K
MASS icon
94
908 Devices
MASS
$414M
– –
-149,315
Closed -$3.07M
PHAT icon
95
Phathom Pharmaceuticals
PHAT
$742M
– –
-69,135
Closed -$583K
RCKT icon
96
Rocket Pharmaceuticals
RCKT
$374M
– –
-26,677
Closed -$367K
ZYME icon
97
Zymeworks
ZYME
$1.77B
– –
-125,806
Closed -$667K
EIGR
98
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,758
Closed -$332K
SURF
99
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-115,577
Closed -$190K
FMTX
100
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-78,603
Closed -$542K
1 2 3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Parkman Healthcare Partners held 100 positions worth $352M, up 30% from $272M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners deployed $76.6M of net new capital in Q3 2022, opening 24 new positions and adding to 44 existing holdings. Its largest new stake was Boston Scientific: 347,787 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was iRhythm Holdings, an estimated $7.01M trimmed.

  • Parkman Healthcare Partners's largest Q3 2022 buy was Boston Scientific: 347,787 shares worth $13.5M.
  • Parkman Healthcare Partners added most to Haemonetics in Q3 2022, an estimated $6.52M increase.
  • Parkman Healthcare Partners's biggest Q3 2022 reduction was iRhythm Holdings, cutting an estimated $7.01M.
  • Parkman Healthcare Partners fully exited Altimmune in Q3 2022, selling an estimated $6.55M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $352M portfolio in Q3 2022.
  • Parkman Healthcare Partners opened 24 new positions and closed 11 in Q3 2022.
  • Parkman Healthcare Partners's portfolio value rose 30% quarter-over-quarter to $352M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.